Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Lexicon Pharmaceuticals, Inc.    LXRX

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 77,4 M
EBIT 2016 -154 M
Net income 2016 -164 M
Debt 2016 38,0 M
Yield 2016 -
Sales 2017 90,3 M
EBIT 2017 -183 M
Net income 2017 -186 M
Debt 2017 81,0 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 20,6x
EV / Sales2017 18,2x
Capitalization 1 558 M
More Financials
Company
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company, focuses on the development of breakthrough treatments for human disease.It has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications.Lexicon Pharmaceuticals was founded... 
More about the company
Surperformance© ratings of Lexicon Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on LEXICON PHARMACEUTICALS, I
11/22 LEXICON PHARMACEUTICALS : To Present At The Stifel 2016 Healthcare Conference An..
11/17 LEXICON PHARMACEUTICALS : Acquires Exclusive Rights To Development Candidate For..
11/16 LEXICON PHARMACEUTICALS : to Report Third Quarter 2016 Financial Results on Nove..
11/10 LEXICON PHARMACEUTICALS : Announces Publication Of TELESTAR Study Results For Te..
11/09 LEXICON PHARMACEUTICALS : buys Bristol neuro drug
11/07 LEXICON PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
11/07 LEXICON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement (form..
11/03 LEXICON PHARMACEUTICALS : To Report Third Quarter 2016 Financial Results On Nove..
11/03 LEXICON PHARMACEUTICALS : Reports Positive Top-Line Results In Phase 2 Dose-Rang..
11/01 LEXICON PHARMACEUTICALS, INC. (NASDA : LXRX) Files An 8-K Provides Clinical Pipe..
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2015 SEEKING ALPHA'S BIOTECH WEEKLY : A Gilead Victory, Celladon Crumbles, And More
2015 Lexicon Undervalued As It Approaches A Major Event
2015 Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q1 2015 Results - Earning..
2015 Lexicon Pharmaceuticals EPS in-line, beats on revenue
2015 Lexicon Pharmaceuticals - A Diamond In The Rough?
Advertisement
Chart LEXICON PHARMACEUTICALS, I
Duration : Period :
Lexicon Pharmaceuticals, I Technical Analysis Chart | LXRX | US5288721047 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 22,8 $
Spread / Average Target 52%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lonnel Coats President, Chief Executive Officer & Director
Raymond Debbane Chairman
Jeffrey L. Wade CFO, EVP-Corporate & Administrative Affairs
Pablo Lapuerta Chief Medical Officer & EVP-Clinical Development
Frank P. Palantoni Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LEXICON PHARMACEUTICAL..12.10%1 558
AMGEN, INC.-11.25%107 132
GILEAD SCIENCES, INC.-27.17%95 410
CELGENE CORPORATION-1.78%91 187
REGENERON PHARMACEUTIC..-31.34%39 310
ACTELION LTD40.40%21 739
More Results